Pseudolaric Acid B

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563685

CAS#: 82508-31-4

Description: Pseudolaric Acid B is an antitumor agent, suppressing the Akt signaling pathway in HeLa cervical cancer cells.


Chemical Structure

img
Pseudolaric Acid B
CAS# 82508-31-4

Theoretical Analysis

MedKoo Cat#: 563685
Name: Pseudolaric Acid B
CAS#: 82508-31-4
Chemical Formula: C23H28O8
Exact Mass: 432.18
Molecular Weight: 432.460
Elemental Analysis: C, 63.88; H, 6.53; O, 29.60

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Pseudolaric Acid B; Pseudolaric Acid-B; (-)-Pseudolaric acid B;

IUPAC/Chemical Name: (2E,4E)-5-((3R,4R,4aS,9aS)-4a-acetoxy-7-(methoxycarbonyl)-3-methyl-1-oxo-3,4,4a,5,6,9-hexahydro-1H-4,9a-ethanocyclohepta[c]pyran-3-yl)-2-methylpenta-2,4-dienoic acid

InChi Key: VDGOFNMYZYBUDT-QZQANUROSA-N

InChi Code: InChI=1S/C23H28O8/c1-14(18(25)26)6-5-10-21(3)17-9-12-22(20(28)31-21)11-7-16(19(27)29-4)8-13-23(17,22)30-15(2)24/h5-7,10,17H,8-9,11-13H2,1-4H3,(H,25,26)/b10-5+,14-6+/t17-,21-,22+,23+/m1/s1

SMILES Code: O=C(O)/C(C)=C/C=C/[C@](O1)(C)[C@]2([H])[C@@]3(OC(C)=O)CCC(C(OC)=O)=CC[C@@](CC2)3C1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 432.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhang J, Han RY, Ye HC, Zhou Y, Zhang ZK, Yuan EL, Li Y, Yan C, Liu X, Feng G, Guo YX. Effect of pseudolaric acid B on biochemical and physiologic characteristics in Colletotrichum gloeosporioides. Pestic Biochem Physiol. 2018 May;147:75-82. doi: 10.1016/j.pestbp.2017.09.006. Epub 2017 Sep 13. PubMed PMID: 29933996.

2: Wang Z, Ding Y, Wang X, Lu S, Wang C, He C, Wang L, Piao M, Chi G, Luo Y, Ge P. Pseudolaric acid B triggers ferroptosis in glioma cells via activation of Nox4 and inhibition of xCT. Cancer Lett. 2018 Aug 1;428:21-33. doi: 10.1016/j.canlet.2018.04.021. Epub 2018 Apr 24. PubMed PMID: 29702192.

3: Li T, Wang W, Li YX, Li X, Ji WJ, Ma YQ, Chen H, Zhao JH, Zhou X. Pseudolaric acid B attenuates atherosclerosis progression and inflammation by suppressing PPARγ-mediated NF-κB activation. Int Immunopharmacol. 2018 Jun;59:76-85. doi: 10.1016/j.intimp.2018.03.041. Epub 2018 Apr 7. PubMed PMID: 29631101.

4: Li S, Guo L. [Pseudolaric acid B induces G2/M arrest and inhibits invasion and migration in HepG2 hepatoma cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018 Jan;34(1):59-64. Chinese. PubMed PMID: 29595459.

5: Wang Y, Gao H, Wu T, Wang Z, Song F, Chen A, Zhang J, Zhang W, Zhang H, Yu J. Pseudolaric acid B induced autophagy, but not apoptosis, in MRC5 human fibroblast cells. Oncol Lett. 2018 Jan;15(1):863-870. doi: 10.3892/ol.2017.7426. Epub 2017 Nov 15. PubMed PMID: 29399151; PubMed Central PMCID: PMC5772809.

6: Song Q, Jiang S, Zhang X, Pan C, Lu C, Peng J, Li Q. Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway. Exp Ther Med. 2018 Jan;15(1):685-690. doi: 10.3892/etm.2017.5500. Epub 2017 Nov 13. PubMed PMID: 29399072; PubMed Central PMCID: PMC5772519.

7: Li X, Zhao X, Song W, Tian Z, Yang L, Niu Q, Zhang Q, Xie M, Zhou B, Xu Y, Wu J, Zhang C. Pseudolaric Acid B Inhibits Proliferation, Invasion and Epithelial-to-Mesenchymal Transition in Human Pancreatic Cancer Cell. Yonsei Med J. 2018 Jan;59(1):20-27. doi: 10.3349/ymj.2018.59.1.20. PubMed PMID: 29214772; PubMed Central PMCID: PMC5725359.

8: Yang Z, Liu M, Wang W, Wang Y, Cao B, Gao Y, Chen H, Li T. Pseudolaric acid B attenuates atopic dermatitis-like skin lesions by inhibiting interleukin-17-induced inflammation. Sci Rep. 2017 Aug 11;7(1):7918. doi: 10.1038/s41598-017-08485-x. PubMed PMID: 28801611; PubMed Central PMCID: PMC5554149.

9: Song F, Yu X, Zhang H, Wang Z, Wang Y, Meng X, Yu J. Pseudolaric acid B inhibits neuroglioma cell proliferation through DNA damage response. Oncol Rep. 2017 Oct;38(4):2211-2218. doi: 10.3892/or.2017.5861. Epub 2017 Aug 1. PubMed PMID: 28765951.

10: Zhou Y, Di Z, Li X, Shan Y, Li W, Zhang H, Xiao Y. Chemical proteomics reveal CD147 as a functional target of pseudolaric acid B in human cancer cells. Chem Commun (Camb). 2017 Aug 11;53(62):8671-8674. doi: 10.1039/c7cc04345g. Epub 2017 Jul 19. PubMed PMID: 28721406.

11: Liu ML, Sun D, Li T, Chen H. A Systematic Review of the Immune-Regulating and Anticancer Activities of Pseudolaric Acid B. Front Pharmacol. 2017 Jun 28;8:394. doi: 10.3389/fphar.2017.00394. eCollection 2017. Review. PubMed PMID: 28701952; PubMed Central PMCID: PMC5487521.

12: Yao GD, Yang J, Li XX, Song XY, Hayashi T, Tashiro SI, Onodera S, Song SJ, Ikejima T. Blocking the utilization of glucose induces the switch from senescence to apoptosis in pseudolaric acid B-treated human lung cancer cells in vitro. Acta Pharmacol Sin. 2017 Oct;38(10):1401-1411. doi: 10.1038/aps.2017.39. Epub 2017 Jun 26. PubMed PMID: 28649131; PubMed Central PMCID: PMC5630671.

13: Wang D, Tian Y, Feng W, Zhao L, Zhao M, Liu J, Wang Q. Pseudolaric acid B induces endometrial cancer Ishikawa cell apoptosis and inhibits metastasis through AKT-GSK-3β and ERK1/2 signaling pathways. Anticancer Drugs. 2017 Jul;28(6):603-612. doi: 10.1097/CAD.0000000000000500. PubMed PMID: 28422767.

14: Wang D, Xin Y, Tian Y, Li W, Sun D, Yang Y. Pseudolaric acid B inhibits gastric cancer cell metastasis in vitro and in haematogenous dissemination model through PI3K/AKT, ERK1/2 and mitochondria-mediated apoptosis pathways. Exp Cell Res. 2017 Mar 1;352(1):34-44. doi: 10.1016/j.yexcr.2017.01.012. Epub 2017 Jan 26. PubMed PMID: 28132880.

15: Mafu S, Karunanithi PS, Palazzo TA, Harrod BL, Rodriguez SM, Mollhoff IN, O'Brien TE, Tong S, Fiehn O, Tantillo DJ, Bohlmann J, Zerbe P. Biosynthesis of the microtubule-destabilizing diterpene pseudolaric acid B from golden larch involves an unusual diterpene synthase. Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):974-979. doi: 10.1073/pnas.1612901114. Epub 2017 Jan 17. PubMed PMID: 28096378; PubMed Central PMCID: PMC5293046.

16: Singh V, He Y, Wang C, Xu J, Xu X, Li H, Singh P, York P, Sun L, Zhang J. A comparison report of three advanced methods for drug-cyclodextrin interaction measurements. J Pharm Biomed Anal. 2017 Feb 5;134:252-258. doi: 10.1016/j.jpba.2016.11.037. Epub 2016 Nov 27. PubMed PMID: 28006703.

17: Yu J, Wang Z, Ren P, Zhong T, Wang Y, Song F, Hou J, Yu X, Hua S. Pseudolaric acid B inhibits the secretion of hepatitis B virus. Oncol Rep. 2017 Jan;37(1):519-525. doi: 10.3892/or.2016.5254. Epub 2016 Nov 16. PubMed PMID: 27878296.

18: Wen C, Chen J, Zhang D, Wang H, Che J, Qin Q, He L, Cai Z, Lin M, Lou Q, Huang L, Chen D, Iwamoto A, Ren D, Wang L, Lan P, Wang J, Liu H, Yang X. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. Cancer Lett. 2016 Dec 28;383(2):295-308. doi: 10.1016/j.canlet.2016.09.007. Epub 2016 Oct 3. PubMed PMID: 27713084.

19: Li Y, Li T, Ji W, Li X, Ma Y, Zhao J, Zhou X, Li Y. [Inhibitory effects of pseudolaric acid B on inflammatory response and M1 phenotype polarization in RAW264.7 macrophages induced by lipopolysaccharide]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 May;32(5):625-9. Chinese. PubMed PMID: 27126941.

20: Yao GD, Yang J, Li Q, Zhang Y, Qi M, Fan SM, Hayashi T, Tashiro S, Onodera S, Ikejima T. Activation of p53 contributes to pseudolaric acid B-induced senescence in human lung cancer cells in vitro. Acta Pharmacol Sin. 2016 Jul;37(7):919-29. doi: 10.1038/aps.2016.8. Epub 2016 Apr 4. PubMed PMID: 27041461; PubMed Central PMCID: PMC4933766.